Liminatus Pharma Inc., based in La Palma, California, has announced the advancement of its novel CD47 checkpoint inhibitor, IBA101, towards human trials in the United States and Korea. This development marks a significant step in the company's efforts to enhance immunotherapy options with a focus on safety and efficacy. IBA101 is engineered to avoid the anemia and thrombocytopenia issues that affected previous candidates, allowing for potentially higher dosing levels and improved anti-tumor responses. Liminatus is preparing its Investigational New Drug $(IND.AU)$ applications for submission to the U.S. Food and Drug Administration and Korea's Ministry of Food and Drug Safety in the second half of 2026. The clinical trials are set to begin in early 2027, with a strategic collaboration established in Seoul, South Korea, to facilitate advanced research on non-small-cell lung cancer. The results of these trials have not yet been presented, as patient screening and site activations are anticipated to commence in early 2027.